Lantern Pharma (LTRN) received FDA clearance for its IND application, allowing LP-184 to enter human testing. The drug targets triple-negative breast cancer (TNBC), an aggressive and hard-to-treat type. Lantern can now start a Phase Ib/II trial, the first study of LP-184 in patients.
